These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

902 related items for PubMed ID: 10871202

  • 1. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [Abstract] [Full Text] [Related]

  • 2. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [Abstract] [Full Text] [Related]

  • 3. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
    Kato K, Yamada D, Midorikawa S, Sato W, Watanabe T.
    Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
    [Abstract] [Full Text] [Related]

  • 4. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J.
    N Engl J Med; 1994 Nov 03; 331(18):1188-93. PubMed ID: 7935656
    [Abstract] [Full Text] [Related]

  • 9. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.
    Diabetes Care; 2002 Mar 01; 25(3):542-9. PubMed ID: 11874944
    [Abstract] [Full Text] [Related]

  • 11. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity?
    Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C, Hainque B.
    Int J Obes Relat Metab Disord; 1995 Nov 01; 19(11):836-8. PubMed ID: 8589788
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug 01; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A, Bayraktar M, Kirazli S.
    Diabetes Care; 2000 Jan 01; 23(1):88-92. PubMed ID: 10857975
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.
    Diabetes; 2002 Feb 01; 51(2):443-8. PubMed ID: 11812753
    [Abstract] [Full Text] [Related]

  • 19. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S.
    Cardiovasc Diabetol; 2011 Mar 18; 10():23. PubMed ID: 21414238
    [Abstract] [Full Text] [Related]

  • 20. Effect of troglitazone on serum gamma-glutamyltransferase activity and plasma t-PA/PAI-1 complex in type 2 diabetic patients.
    Koh H, Akiyama Y, Yui K.
    Arzneimittelforschung; 2006 Mar 18; 56(4):288-94. PubMed ID: 16724515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.